{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Number of patients, whose Serum Ferritin levels are lower than 1500 ng/mL at two consecutive study visits. Serum Ferritin levels are measured at screening (baseline), week 4, 8, 12, 16, 20, 24 and end of study.","groups":[{"description":"Patients receive oral deferasirox once daily for up to 6 months in the absence of unacceptable toxicity.","id":"OG000","title":"Arm I"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Assessed through 6 months from the start of treatment","title":"Number of Patients With Serum Ferritin Level Lower Than 1500 ng/mL After Treatment","type":"SECONDARY","unitOfMeasure":"Participants"}